GILD is buying IMMU for the third line triple negative breast cancer drug sacituzumab govitecan. That drug is just ok. Progression free survival is 5.5 months. Investors over there are probably thrilled. They can stay happy until leronlimab gets approved and they realized GILD wasted $20 billion.